From May 2021, APACMed will launch a monthly health dialogue for our members and partners in the region, providing key insights into the MedTech Industry in China. The APACMed China Health Dialogue Series will cover trends and key topics including polices, regulations, market insights and opportunities to support our members’ market-appropriate strategies in China.

To kick off our first monthly discussion, we will discuss Diagnosis-Related Group (DRG), a hot policy launched by China’s National Healthcare Security Administration (NHSA) in 2019, which is currently being piloted in 30 Chinese cities and will be fully implemented by the end of 2021. This discussion will delve into the following topics in depth:

1. Policy considerations in designing and implementing DRG policy in pilot cities.
2. Requirements and impacts on medical institutions.
3. Demonstrating the value of innovation in DRG policy implementation.
4. Suggestions and future trend analysis for the MedTech industry.

Link to the deck: DRG Implementation of WH

Link to the deck: Health Financing Reform in China